TargetMol

Emtricitabine

Product Code:
 
TAR-T6214
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6214-50mg50mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6214-100mg100mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6214-500mg500mg£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Emtricitabine (FTC), a nucleoside reverse transcriptase inhibitor, exhibits inhibition activity against human immunodeficiency virus (HIV) and hepatitis B virus.
CAS:
143491-57-0
Formula:
C8H10FN3O3S
Molecular Weight:
247.24
Pathway:
Proteases/Proteasome; Microbiology/Virology
Purity:
0.9993
SMILES:
Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1
Target:
HIV Protease; Reverse Transcriptase

References

Venhoff N, et al. Antivir Ther, 2007, 12(7), 1075-1085. Borroto-Esoda K, et al. Antivir Ther, 2006, 11(3), 377-384. Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692. Bao H, Yan J, Huang J, et al.Activation of endogenous retrovirus triggers microglial immuno-inflammation and contributes to negative emotional behaviors in mice with chronic stress.Journal of Neuroinflammation.2023, 20(1): 1-16. Richman DD, et al. Antivir Ther, 2001, 6(2), 83-88. Faltz M, et al. Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP. Cardiovasc Toxicol. 2017 Jan 3. [Epub ahead of print] Hazen R, et al. J Acquir Immune Defic Syndr, 2003, 32(3), 255-258. Saag MS, et al. Clin Infect Dis, 2006, 42(1), 126-131.